Talniflumatum

Talniflumatum Uses, Dosage, Side Effects, Food Interaction and all others data.

Talniflumatum, is an anti-inflammatory molecule studied and used as a mucin regulator in the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma . In addition, it is used in inflammatory conditions such as rheumatoid arthritis. Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this research has now been discontinued . Talniflumatum has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) .

Talniflumatum is metabolized to its prodrug, niflumic acid, which has several pharmacodynamic effects. Firstly, it blocks synthesis of mucin. Secondly, talniflumate blocks prostaglandin synthesis by cyclooxygenases, which aids in pain and inflammation management.

Talniflumatum
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Talniflumatum
Generic	Talniflumate
Talniflumate Other Names	Talniflumate, Talniflumato, Talniflumatum
Type
Formula	C₂₁H₁₃F₃N₂O₄
Weight	Average: 414.34 Monoisotopic: 414.082741396
Protein binding	Niflumic acid, the active form of Talniflumate, is weak acid that is strongly bound to plasma proteins. Bioavailability was 100% in a study of 12 volunteers. It is a weak acid, strongly bound to plasma proteins .
Groups	Experimental
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Talnifumate is a phthalidyl ester of nifumic acid, which has potent analgesic and anti-inflammatory effects and is widely used to treat inflammatory disorders, such as rheumatoid arthritis and osteoarthritis , and has also been studied for the management of cystic fibrosis .

How Talniflumatum works

Talniflumatum is a strong and selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase). Talniflumatum decreases gene expression of GCNT3 and production of mucins in vivo and in vitro. Talniflumatum improves response of pancreatic tumors to gefitinib (chemotherapy drug). Talniflumatum is a strong calcium-activated chloride channel (CaCC) blocker.

Toxicity

LD50 orally in rats: 12000 mg/kg

Volume of Distribution

In 12 subjects after a single oral administration, total plasma clearance of the main metabolite, niflumic acid, averaged 45 ml/min giving a distribution volume of 0.12 l/kg on average .